Notably, two independent studies revealed the co-treatment with proteasome inhibitors (Bortezomib or Carfilzomib) boost the efficiency of anti-B cell maturation antigen (anti-BCMA) Chimeric antigen receptor T (CAR-T) cell in multiple myeloma animal model and human patients via blocking the proteasome mediated degradation of BCMA to stabilize its in cell membrane 93, 94. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.